Elton Zeqiraj

Elton Zeqiraj

Auto-generated profile, based on publicly available information

Elton Zeqiraj

Astbury Centre for Structural Molecular Biology, School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, UK

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 December 2009 in Science
Verified
Journal Article
Closed access
PDF file
EZElton Zeqiraj
Elton Zeqiraj
BFBeatrice Maria Filippi
Beatrice Maria Filippi
MDMaria Deak
Maria Deak
DADario R. Alessi
Dario R. Alessi
DADaan MF Van Aalten
Daan MF Van Aalten
Solving Pseudokinases: Mutations of the protein kinase LKB1 are associated with cancer in humans. Many kinases are activated by phosphorylation, but LKB1 is activated by STRADα, a pseudokinase that is similar to protein kinases and binds ATP, but does not phosphorylate substrates. By solving the crystal structure of an activating complex containing LKB, Zeqiraj et al. (p. 1707 , published online 5 November) show that STRADα works with another protein, MO25α, to hold LKB1 in an active conformation. The results may help explain the evolutionary origin of pseudokinases, the biological roles of other pseudokinases, and the mechanisms of disease-causing mutations in LKB1.

27 August 2018 in Nature Medicine
Verified
Journal Article
Open access
PDF file
RHRoger W. Hunter
Roger W. Hunter
CHCurtis C. Hughey
Curtis C. Hughey
LLLouise Lantier
Louise Lantier
ESElias I. Sundelin
Elias I. Sundelin
MPMark Peggie
Mark Peggie
KSKei Sakamoto
Kei Sakamoto
Metformin is a first-line drug for the treatment of individuals with type 2 diabetes, yet its precise mechanism of action remains unclear. Metformin exerts its antihyperglycemic action primarily through lowering hepatic glucose production (HGP). This suppression is thought to be mediated through inhibition of mitochondrial respiratory complex I, and thus elevation of 5′-adenosine monophosphate (AMP) levels and the activation of AMP-activated protein kinase (AMPK), though this proposition has been challenged given results in mice lacking hepatic AMPK. Here we report that the AMP-inhibited enzyme fructose-1,6-bisphosphatase-1 (FBP1), a rate-controlling enzyme in gluconeogenesis, functions as a major contributor to the therapeutic action of metformin. We identified a point mutation in FBP1 that renders it insensitive to AMP while sparing regulation by fructose-2,6-bisphosphate (F-2,6-P2), and knock-in (KI) of this mutant in mice significantly reduces their response to metformin treatment. We observe this during a metformin tolerance test and in a metformin-euglycemic clamp that we have developed. The antihyperglycemic effect of metformin in high-fat diet–fed diabetic FBP1-KI mice was also significantly blunted compared to wild-type controls. Collectively, we show a new mechanism of action for metformin and provide further evidence that molecular targeting of FBP1 can have antihyperglycemic effects.

1 February 2013 in Science
Verified
Journal Article
Closed access
PDF file
AEAndreas Ernst
Andreas Ernst
GAGeorge Avvakumov
George Avvakumov
JTJiefei Tong
Jiefei Tong
YFYihui Fan
Yihui Fan
YZYanling Zhao
Yanling Zhao
SSSachdev Sidhu
Sachdev Sidhu
Modifying Deubiquitinases: Protein ubiquitination is a widespread mechanism for cellular regulation, and new regulators are valuable research tools and may help to generate therapeutic small molecules. Ernst et al. (p. 590 , published online 3 January) used known crystal structures to roughly define the interaction domain between a ubiquitin-specific protease and a ubiquitinated substrate and then screened ubiquitin variants with changes in these residues to find variants that acted as potent and specific regulators that could modify ubiquitin pathway regulation in cells.

1 December 2010 in Current Opinion in Structural Biology
Verified
Journal Article
Open access
EZElton Zeqiraj
Elton Zeqiraj
DADaan MF Van Aalten
Daan MF Van Aalten
Protein kinases provide a platform for the integration of signal transduction networks. A key feature of transmitting these cellular signals is the ability of protein kinases to activate one another by phosphorylation. A number of kinases are predicted by sequence homology to be incapable of phosphoryl group transfer due to degradation of their catalytic motifs. These are termed pseudokinases and because of the assumed lack of phosphoryltransfer activity their biological role in cellular transduction has been mysterious. Recent structure-function studies have uncovered the molecular determinants for protein kinase inactivity and have shed light to the biological functions and evolution of this enigmatic subset of the human kinome. Pseudokinases act as signal transducers by bringing together components of signalling networks, as well as allosteric activators of active protein kinases.

9 June 2009 in PLOS Biology
Verified
Journal Article
Open access
PDF file
EZElton Zeqiraj
Elton Zeqiraj
BFBeatrice Maria Filippi
Beatrice Maria Filippi
SGSimon Goldie
Simon Goldie
INIva Navratilova
Iva Navratilova
JBJérôme Boudeau
Jérôme Boudeau
DADaan MF Van Aalten
Daan MF Van Aalten
Pseudokinases lack essential residues for kinase activity, yet are emerging as important regulators of signal transduction networks. The pseudokinase STRAD activates the LKB1 tumour suppressor by forming a heterotrimeric complex with LKB1 and the scaffolding protein MO25. Here, we describe the structure of STRADα in complex with MO25α. The structure reveals an intricate web of interactions between STRADα and MO25α involving the αC-helix of STRADα, reminiscent of the mechanism by which CDK2 interacts with cyclin A. Surprisingly, STRADα binds ATP and displays a closed conformation and an ordered activation loop, typical of active protein kinases. Inactivity is accounted for by nonconservative substitution of almost all essential catalytic residues. We demonstrate that binding of ATP enhances the affinity of STRADα for MO25α, and conversely, binding of MO25α promotes interaction of STRADα with ATP. Mutagenesis studies reveal that association of STRADα with either ATP or MO25α is essential for LKB1 activation. We conclude that ATP and MO25α cooperate to maintain STRADα in an “active” closed conformation required for LKB1 activation. It has recently been demonstrated that a mutation in human STRADα that truncates a C-terminal region of the pseudokinase domain leads to the polyhydramnios, megalencephaly, symptomatic epilepsy (PMSE) syndrome. We demonstrate this mutation destabilizes STRADα and prevents association with LKB1. In summary, our findings describe one of the first structures of a genuinely inactive pseudokinase. The ability of STRADα to activate LKB1 is dependent on a closed “active” conformation, aided by ATP and MO25α binding. Thus, the function of STRADα is mediated through an active kinase conformation rather than kinase activity. It is possible that other pseudokinases exert their function through nucleotide binding and active conformations. There are 518 human protein kinases that are responsible for orchestrating the phosphorylation-dependant signal transduction events that regulate almost all cellular processes. Curiously, approximately 10% of protein kinases lack one or more catalytic residues, and these kinases have been termed pseudokinases. It has been proposed that some pseudokinases act as scaffolds, bringing together proteins involved in signalling networks. Here, we report the structure of the pseudokinase STRADα in complex with the adaptor protein MO25α; together these two proteins regulate the LKB1 tumour suppressor kinase. Despite lacking several key catalytic residues, STRADα binds ATP and adopts an active conformation typical of catalytically competent kinases. The affinity of STRADα for ATP is enhanced by MO25α and vice versa. We go on to demonstrate through mutagenesis studies that binding to both ATP and MO25α is essential for the activation of LKB1. Our data suggest that STRADα exerts its functions through an active conformation, not through actual catalytic activity, thus raising the possibility that pseudokinases regulate signalling networks by adopting different structural conformations.

1 January 2014 in Molecular Cell
Verified
Journal Article
Closed access
HHHao Huang
Hao Huang
EZElton Zeqiraj
Elton Zeqiraj
BDBeihua Dong
Beihua Dong
Babal Kant JhaBabal Kant Jha
Babal Kant Jha
NDNicole M. Duffy
Nicole M. Duffy
FSFrank Sicheri
Frank Sicheri